International Journal of Women's Health (Feb 2023)
Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives
Abstract
Saira J Khan,1 Ekta Kapoor,2– 4 Stephanie S Faubion,2,5 Juliana M Kling2,6 1Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA; 2Mayo Clinic Women’s Health, Rochester, MN, USA; 3Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 4Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA; 5Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, USA; 6Division of Women’s Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, USACorrespondence: Juliana M Kling, Division of Women’s Health Internal Medicine, Mayo Clinic, 13737 N 92 23 nd St, Scottsdale, AZ, 85260, USA, Tel +1-480-614-6001, Fax +1-480-614-6021, Email [email protected]: Vasomotor symptoms affect as many as 80% of midlife women, but only about one in four women receive treatment due to many factors. Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms, and current professional guidelines conclude that the benefits of treatment typically outweigh the risks for healthy, symptomatic women under age 60 years and those within 10 years from their final menstrual period. For women with medical comorbidities, an individualized approach to treatment is recommended. For women who cannot use or choose not to use menopausal hormone therapy, there are many evidence-based non-hormonal options available including pharmacologic therapies. This review aims to summarize treatment options for bothersome vasomotor symptoms to guide clinicians caring for midlife women.Keywords: menopause, vasomotor symptoms, menopausal hormone therapy, non-hormonal treatments
